This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

ifa systems Valuation

Is IS8 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of IS8 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate IS8's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate IS8's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IS8?

Key metric: As IS8 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for IS8. This is calculated by dividing IS8's market cap by their current earnings.
What is IS8's PE Ratio?
PE Ratio	16.2x
Earnings	€448.00k
Market Cap	€7.26m

IS8 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.8x
Enterprise Value/EBITDA	3.5x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does IS8's PE Ratio compare to its peers?

The above table shows the PE ratio for IS8 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	25.3x
M3V MeVis Medical Solutions	7.7x	n/a	€44.4m
AJ91 DocCheck	16.9x	n/a	€41.4m
COP CompuGroup Medical SE KGaA	32.3x	32.9%	€786.4m
NXU Nexus	44.1x	17.1%	€1.2b
IS8 ifa systems	16.2x	n/a	€7.3m

Price-To-Earnings vs Peers: IS8 is good value based on its Price-To-Earnings Ratio (16.2x) compared to the peer average (21.5x).

Price to Earnings Ratio vs Industry

How does IS8's PE Ratio compare vs other companies in the European Healthcare Services Industry?

2 Companies	Price / Earnings	Estimated Growth	Market Cap

2 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: IS8 is good value based on its Price-To-Earnings Ratio (16.2x) compared to the European Healthcare Services industry average (34.1x).

Price to Earnings Ratio vs Fair Ratio

What is IS8's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IS8 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	16.2x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate IS8's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Sensus Healthcare

US$143.9m

A medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide.

5TX

US$8.25

4.4%

263.8%

Shandong Weigao Group Medical Polymer

HK$20.2b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.52

-1.9%

-37.7%

LNA Santé

€240.3m

Engages in the management and operation of health establishments.

2N3

€23.00

1.5%

17.7%